Biosensors International

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Biosensors International" – news · newspapers · books · scholar · JSTOR (March 2010) (Learn how and when to remove this message)

|

Biosensors International Group, Ltd.

Company type| Public (SGX: B20 )
Industry| Medical technology
Founded| unknown
Headquarters| Singapore

Key people

| Lu Yoh-Chie, Chairman and founding CEO; Mike Kleine, CEO
Products| Medical devices
Revenue| USD $37.8 Million (2006)
Website| www.biosensors.com

Medical device company based in Singapore

Biosensors International Group, Ltd. is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company was listed on the mainboard of the Singapore Exchange (SGX) in May 2005.

The global headquarters of the company is located in Singapore and holds the main manufacturing facilities and research and development centers. The European headquarters are in Morges, Switzerland. The Swiss office is also the legal manufacturer of BioMatrix, the company's current leading product. Biosensors International also licenses its proprietary drug-eluting stent technologies to other medical device companies and specialty stent providers, including Terumo, Devax, Inc., and Xtent, Inc.

Biosensors International Group has a joint-venture in Hong Kong listed as Shandong Weigao to market and distribute coronary stents in China.[1]

## BioMatrix

[edit]

BioMatrix is a drug-eluting stent that utilizes proprietary technologies of Biosensors International:

* A biodegradable Poly-Lactic Acid (PLA) polymer, which degrades into the naturally occurring lactic acid.[2]
* The Biolimus A9 drug, a highly lipophilic derivative of sirolimus.
* The S-Stent stent platform.
* An automated stent coating technology that directly deposits the coating onto the stent surface.[3]

Biosensors obtained approval for this drug-eluting stent product in January 2008.

## See also

[edit]

* Drug-eluting stent
* Biolimus A9

## Notes

[edit]

1. ^ Unknown.Biosensors and Weigao Sign Letter of Intent and Expand Business Collaboration[permanent dead link], Biosensors Investor Relations
2. ^ Yazdani, Saami; Vorpahl, Marc; Nakano, Masataka; Su, Shih-Horng; Kolodgie, Frank; Virmani, Renu. "In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent". eurointervention.pcronline.com. Retrieved 2025-02-14.
3. ^ CA2705764A1, Vecerina, Ivan & Pham, Vinh, "Automated stent coating apparatus and method", issued 2009-05-22

## External links

[edit]

* Biosensors International Website

Authority control databases |

* ISNI

|

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template